Clostridium Difficile-Associated Diarrhea News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

CutisPharma Announces FDA Approval Of FIRVANQ? For Treatment Of Clostridium Difficile Associated Diarrhea ... - PR Newswire (press release)



Contagionlive.com
 
CutisPharma Announces FDA Approval Of FIRVANQ? For Treatment Of Clostridium Difficile Associated Diarrhea ... 
PR Newswire (press release)
"FIRVANQ's approval is an important step forward to providing patients the only FDA-approved vancomycin oral liquid treatment option for Clostridium difficile associated diarrhea, a life-threatening condition that affects over a half-million patients ...
Firvanq Approved for C. difficile-Associated Diarrhea, S. aureus Colitis Monthly Prescribing Reference
FDA approves first oral liquid treatment for C. difficile-associated diarrhea Healio
FDA Approves Vancomycin Hydrochloride for Treatment of CDAD & Staphylococcus aureus Enterocolitis Contagionlive.com
Infectious Disease Advisor  -Pharmacy Times  -CIDRAP 
all 9 news articles » 


FDA OKs First Vancomycin Oral Solution for C diff Diarrhea - Medscape



Medscape
 
FDA OKs First Vancomycin Oral Solution for C diff Diarrhea 
Medscape
The US Food and Drug Administration (FDA) has approved vancomycin hydrochloride for oral solution (Firvanq, CutisPharma) for the treatment of Clostridium difficile?associated diarrhea (CDAD) and enterocolitis caused by Staphylococcus aureus, including ...
CutisPharma wins FDA approval of oral liquid vancomycin BioPharma Dive

all 2 news articles » 


Melinta Therapeutics' Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for ... - GlobeNewswire (press release)



Melinta Therapeutics' Commercial Partner Eurofarma Laboratórios Submits Marketing Authorization Application for ... 
GlobeNewswire (press release)
NEW HAVEN, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that Eurofarma Laboratórios ...

and more » 


CutisPharma announces FDA approval of vancomycin hydrochloride for treatment of CDAD and Staphylococcus ... - Pharmacy Today, American Pharmacists Association, pharmacist.com



CutisPharma announces FDA approval of vancomycin hydrochloride for treatment of CDAD and Staphylococcus ... 
Pharmacy Today, American Pharmacists Association, pharmacist.com
FDA has approved vancomycin hydrochloride (Firvanq&#8212;CutisPharma) for oral solution, for the treatment of <i>Clostridium difficile</i>-associated diarrhea (CDAD) and enterocolitis caused by <i>Staphylococcus aureus</i>, including methicillin ...

 


High-Touch Wipe Down: Decreasing C. diff Rates in Adults With Cancer - www.oncnursingnews.com/



www.oncnursingnews.com/
 
High-Touch Wipe Down: Decreasing C. diff Rates in Adults With Cancer 
www.oncnursingnews.com/
Clostridium difficile (C. diff) is a gram-positive, spore-forming bacterium noted to be the leading cause of hospital-acquired diarrhea in patients with cancer undergoing chemotherapy.1 A study by Kamboj et al reported C. diff rates to be twice as high ...

 


Wilmington CutisPharma announces FDA approval - Wicked Local Wilmington



Wilmington CutisPharma announces FDA approval 
Wicked Local Wilmington
WILMINGTON ? CutisPharma announced that the US Food and Drug Administration has approved FIRVANQ (vancomycin hydrochloride) for oral solution for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus ...

 


Head-To-Head Review: Jaguar Health (NASDAQ:JAGX) & Shire Viropharma (VPHM) - The Lincolnian Online



Head-To-Head Review: Jaguar Health (NASDAQ:JAGX) & Shire Viropharma (VPHM) 
The Lincolnian Online
Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated ...

and more » 


4 latest FDA approvals - Becker's Hospital Review



4 latest FDA approvals 
Becker's Hospital Review
Here are the four latest drugs or medical devices approved by the FDA since Jan. 12. 1. Firvanq is a vancomycin hydrochloride oral solution used to treat Clostridium difficile-associated diarrhea and Staphylococcus aureus-associated intestinal ...

 


Melinta Therapeutics Launches Antibiotic Baxdela? (delafloxacin) in the United States - GlobeNewswire (press release)



Melinta Therapeutics Launches Antibiotic Baxdela? (delafloxacin) in the United States 
GlobeNewswire (press release)
NEW HAVEN, Conn., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the U.S. launch of ...

and more » 


US FDA approves CutisPharma's Firvanq to treat CDAD and staphylococcus aureus colitis - pharmabiz.com



US FDA approves CutisPharma's Firvanq to treat CDAD and staphylococcus aureus colitis 
pharmabiz.com
CutisPharma announced that the US Food and Drug Administration (FDA) has approved Firvanq (vancomycin hydrochloride) for oral solution, for the treatment of Clostridium difficile associated diarrhea (CDAD) and enterocolitis caused by Staphylococcus ...